Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

Vaccine

Volumn 26, Issue 12, 2008, Pages 1525-1529

  Ansaldi, Filippo ^a   Bacilieri, Sabrina ^a   Durando, Paolo ^a   Sticchi, Laura ^a   Valle, Laura ^a   Montomoli, Emanuele ^b   Icardi, Giancarlo ^a   Gasparini, Roberto ^a   Crovari, Pietro ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Antigenic drift; Cross protection; Influenza; MF59

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; HEMAGGLUTINATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SINGLE DRUG DOSE; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 40049111382     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.019     Document Type: Article

References (19)

1. J.C. de Jong W.E.P. Beyer A.M. Palanche G.F. Rimmelzwaan A.D.M.E. Osterhaus Mismatch between the 1997/98 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly J Med Virol 61 2000 94 99
2. F. Ansaldi S. Bacilieri F. Banfi P. Durando L. Sticchi G. Icardi Neutralizing and hemagglutination-inhibiting activity of antibodies elicited by the 2004–2005 influenza vaccine against drifted viruses Clin Vaccine Immunol 13 2006 162 164
3. G. Del Giudice A.K. Hilbert R. Bugarini A. Minutello O. Popova D. Toneatto An MF59-adjuvanted inactivated vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza strain A/Fujian/2002 than a subunit and a split influenza vaccine Vaccine 24 2006 3063 3065
4. N. Kojimahara A. Maeda T. Kase N. Yamaguchi Cross-reactivity of influenza A(H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine Vaccine 24 2006 5966 5969
5. M. Zambon Laboratory diagnosis of influenza K.G. Nicholson R.G. Webster A.J. Hay Textbook of influenza 1998 Blackwell Science Oxford 291 313
6. A.M. Iorio M. Neri E. Lepri B. Camilloni M. Basileo N. Sigismondi An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home Vaccine 24 2006 6615 6619
7. C.A. Benne M. Harmsen J.C. De Jong C.A. Kraaijeveld Neutralization enzyme immunoassay for influenza virus J Clin Microbiol 32 1994 987 990
8. F. Carrat A. Flahault Influenza vaccine: the challenge of antigenic drift Vaccine 25 2007 6852 6862
9. V. Baldo T. Baldovin A. Floreani E. Fragapane R. Trivello Response of influenza against heterovariant influenza virus strains in adults with chronic diseases J Clin Immunol 27 2007 542 547
10. T. Rowe R.A. Abernathy J. Hu-Primmer W.W. Thompson X. Lu W. Lim Detection of antibody to avian influenza A(H5N1) virus in human serum by using a combination of serologic assays J Clin Microbiol 37 1999 937 943
11. W.E.P. Beyer A.M. Palanche G. Luchters J. Nauta A.D.M.E. Osterhaus Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103 2004 125 132
12. A. Podda The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine Vaccine 19 2001 2673 2680
13. R. Gasparini T. Pozzi E. Montomoli E. Fragapane M. Minutello A. Podda Increased immunogenicity of the MF59- adjuvanted vaccine compared to a conventional vaccine in elderly subjects Eur J Epidemiol 17 2001 135 140
14. S. De Donato D. Granoff M. Minutello G. Lecchi M. Faccini M. Agnello Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly Vaccine 17 1999 3094 3101
15. M. Minutello F. Senatore G. Cecchinelli M. Bianchi T. Andreani A. Podda Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons Vaccine 17 1999 99 104
16. WHO Influenza Centre, London. Characteristics of human influenza AH1N1, AH3N2 and B viruses isolated January to September 2006. Interim Report; September 2006. Available online at: http://www.nimr.mrc.ac.uk/wic/report/ .
17. F. Ansaldi G. Icardi R. Gasparini C. Campello S. Puzelli A. Bella New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004–2005 season J Clin Microbiol 43 2005 3027 3029
18. I.R. Stephenson R. Bugarini K.G. Nicholson A. Podda J.M. Wood M.C. Zambon Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97(H5N3) vaccine: a potential priming strategy J Infect Dis 191 2005 1210 1215
19. World Health Organization. Recommendations for influenza vaccines; 2007. Available online at: http://www.who.int/csr/disease/influenza/vaccinerecommendations/en/index.html .